Contrast enhanced brain CT. Comparison between iohexol and metrizoate.
The commonly used contrast medium metrizoate (Isopaque Cerebral) or the new nonionic iohexol were injected intravenously for enhancement of cranial CT in a randomized double blind study. Each group consisted of 105 patients. No serious reactions occurred. Ten patients receiving metrizoate had minor reactions of mainly allergic type, whereas only one patient receiving iohexol reacted. No differences in enhancement efficiency could be observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D006801:Humans; D007463:Iodobenzoates / Q000009:adverse effects*; D007472:Iohexol; D008297:Male; D008794:Metrizoic Acid / Q000009:adverse effects*; D008875:Middle Aged; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids / Q000009:adverse effects*
D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D008794:Metrizoic Acid